Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
One major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …
costly cocktails to reduce emergence of antibody resistance. Here we engineer two …
Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2
Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …
interventions against COVID-19 disease. However, their common genetic and biologic …
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B. 1.1. 529
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …
A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …
variants with increased transmissibility and potential resistance, antibodies and vaccines …
[HTML][HTML] Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing
antibodies and one of the most rapidly evolving domains, which can result in the emergence …
antibodies and one of the most rapidly evolving domains, which can result in the emergence …
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
T Noy-Porat, E Makdasi, R Alcalay, A Mechaly… - Nature …, 2020 - nature.com
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
protection of individuals and populations against SARS-CoV-2. Moreover, passively …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Understanding the molecular basis for immune recognition of SARS-CoV-2 spike
glycoprotein antigenic sites will inform the development of improved therapeutics. We …
glycoprotein antigenic sites will inform the development of improved therapeutics. We …